Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 15Ovarian Neoplasms 11Uterine Cervical Neoplasms 5Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Neoplasms 2Colorectal Neoplasms 2Carcinoma 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Carcinosarcoma 1MMRd/MSI-H Stage II-III Endometrial Cancer 1Lung Neoplasms 1Gestational Trophoblastic Disease 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Clear Cell 1

Interventions

Methotrexate 6Dactinomycin 6Drug Therapy 4camrelizumab 3Vacuum Curettage 3Flow Cytometry 3toripalimab 2pembrolizumab 2apatinib 2Psychiatric Rehabilitation 2Methylprednisolone 2Leucovorin 2Immunologic Techniques 2Filgrastim 2Etoposide 2Cyclophosphamide 2Carboplatin 2Alemtuzumab 2zimberelimab 1sargramostim 1dostarlimab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carotuximab 1aldesleukin 1Vincristine 1Thrombopoietin 1Tacrolimus 1Surveys and Questionnaires 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gestational Trophoblastic Disease × dostarlimab × Gynecologic × Clear all
NCT05405192 2023-02-28

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

University of Miami

Phase 2 Withdrawn
Gynecologic

Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡